BidaskClub Downgrades Dermira (NASDAQ:DERM) to Hold

BidaskClub lowered shares of Dermira (NASDAQ:DERM) from a buy rating to a hold rating in a report published on Tuesday, January 9th.

Other analysts also recently issued reports about the stock. Needham & Company LLC restated a buy rating and issued a $43.00 target price (down from $46.00) on shares of Dermira in a report on Tuesday, November 7th. Cantor Fitzgerald reiterated a buy rating and set a $45.00 price target on shares of Dermira in a report on Monday, November 6th. Guggenheim reiterated a buy rating and set a $30.00 price target on shares of Dermira in a report on Thursday, December 14th. Mizuho cut their price target on shares of Dermira from $43.00 to $39.00 and set a buy rating on the stock in a report on Tuesday, December 12th. Finally, Leerink Swann reiterated an outperform rating and set a $41.00 price target (down from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. Dermira has an average rating of Hold and an average price target of $42.17.

Dermira (NASDAQ:DERM) traded up $0.23 during trading on Tuesday, hitting $28.21. 394,052 shares of the stock were exchanged, compared to its average volume of 579,905. Dermira has a 12-month low of $21.35 and a 12-month high of $38.75. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68. The company has a market cap of $1,190.00, a P/E ratio of -4.53 and a beta of 0.80.

Dermira (NASDAQ:DERM) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.09). Dermira had a negative return on equity of 41.22% and a negative net margin of 992.18%. sell-side analysts forecast that Dermira will post -7.36 earnings per share for the current year.

In related news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $27.34, for a total transaction of $82,020.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total transaction of $499,288.90. The disclosure for this sale can be found here. Insiders sold a total of 36,258 shares of company stock valued at $985,873 in the last ninety days. Corporate insiders own 13.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA increased its stake in Dermira by 2,220.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 3,975 shares in the last quarter. Quantbot Technologies LP increased its stake in Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,309 shares in the last quarter. SG Americas Securities LLC increased its stake in Dermira by 66.8% during the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 2,203 shares in the last quarter. Legal & General Group Plc increased its stake in Dermira by 40.9% during the 2nd quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,803 shares in the last quarter. Finally, Ardsley Advisory Partners acquired a new position in Dermira during the 2nd quarter valued at approximately $291,000. Hedge funds and other institutional investors own 99.47% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “BidaskClub Downgrades Dermira (NASDAQ:DERM) to Hold” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/01/20/dermira-derm-cut-to-hold-at-bidaskclub.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply